{"componentChunkName":"component---src-templates-chapter-level-1-chapter-level-1-tsx","path":"/topics/corticosteroids-oral/have-i-got-the-right-topic/","result":{"pageContext":{"chapter":{"id":"5db581e9-0a76-58c3-9dc7-3d70e2258a58","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","depth":1,"htmlHeader":"<!-- begin field 8d0f16d7-dee7-4bf1-92b8-5a53f456efef --><h1>Have I got the right topic?</h1><!-- end field 8d0f16d7-dee7-4bf1-92b8-5a53f456efef -->","summary":null,"htmlStringContent":"<!-- begin item 7c490d42-de30-425a-ad3c-01d8a2d6d395 --><!-- begin field a07d4658-7216-4052-8214-acd900ae04c9 --><p>From birth onwards.</p><!-- end field a07d4658-7216-4052-8214-acd900ae04c9 --><!-- begin field e11dd7f9-addd-46e5-9937-16b193b7c297 --><p>This CKS topic is largely based on expert opinion in the textbooks <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'segoe ui', Roboto, Oxygen, Ubuntu, Cantarell, 'open sans', 'helvetica neue', sans-serif;\">Rang and Dale's Pharmacology</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Ritter, 2020</a>], <em>Meyler's side effects of endocrine and metabolic drugs</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Aronson, 2009</a>], the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Joint Formulary Committee, 2020</a>], a drug reference compendium <em>Martindale: the complete drug reference </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">Brayfield, 2020</a>], and the manufacturer's Summary of Product Characteristics for prednisolone tablets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2020</a>]. </p><p>This CKS topic covers the management of people receiving oral corticosteroids in primary care. This CKS topic focuses mainly on glucocorticoids. </p><p>This CKS topic does not cover information on the management of the specific condition for which the person is taking oral corticosteroids, and does not cover information on drug doses.</p><p>The target audience for this CKS topic is healthcare professionals working within the NHS in the UK, and providing first contact or primary healthcare.</p><!-- end field e11dd7f9-addd-46e5-9937-16b193b7c297 --><!-- end item 7c490d42-de30-425a-ad3c-01d8a2d6d395 -->","topic":{"id":"2ddb5306-0521-5967-b3ad-e150e92dd71e","topicId":"72c594bc-4c91-4d24-acdb-dda9812ea656","topicName":"Corticosteroids - oral","slug":"corticosteroids-oral","lastRevised":"Last revised in June 2020","chapters":[{"id":"de758570-b276-5b9a-b679-243ca11b5b0b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5db581e9-0a76-58c3-9dc7-3d70e2258a58","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"083ae2c1-9fcd-56d9-9391-3b874be632d6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0863d2e0-89c0-59ea-8c15-e1b41fbd8d5d","slug":"changes","fullItemName":"Changes"},{"id":"1684d913-6ee4-5c81-b8f5-da290e6b10d2","slug":"update","fullItemName":"Update"}]},{"id":"e478b1f3-4d1b-57d5-879f-ad9022a2ec8f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d57df389-307f-59f5-a5e5-f223861afaba","slug":"goals","fullItemName":"Goals"},{"id":"70adac45-ee10-56f9-b88b-e75007cba584","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fe005751-eb99-5634-a99d-041d841fd184","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"854fdd1a-f9cd-5b0f-95b0-ce2693d04cc8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"03f7459a-9d10-5435-af19-3cb0a39f0a88","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7c4a3b4a-3bfd-5b18-b16c-3350018754f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c243f116-7197-5797-8dea-f74bd970f4d7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f776021e-e349-55a4-b655-4801dd7df8e5","slug":"definition","fullItemName":"Definition"},{"id":"241b5d44-7190-5d40-a453-c34255ed8c09","slug":"properties-of-corticosteroids","fullItemName":"Properties of corticosteroids"},{"id":"7cede1e7-70ca-59b2-a0b2-9da96d75e581","slug":"types-of-oral-corticosteroids","fullItemName":"Types of oral corticosteroids"},{"id":"00d48a00-08ac-5b67-a81d-79c587633318","slug":"equivalent-anti-inflammatory-doses","fullItemName":"Equivalent anti-inflammatory doses"}]},{"id":"2d718114-cca8-5be3-9f3b-cd6855079736","fullItemName":"Management","slug":"management","subChapters":[{"id":"84dd471a-9a74-5be7-b888-438a149d76de","slug":"corticosteroids","fullItemName":"Scenario: Corticosteroids"}]},{"id":"6e288e6d-366d-5598-be63-4261ab6000a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cd130a7b-8ddf-543d-a4d2-e2b78c7ebe73","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3b37794e-a5f1-56b1-a7e0-230805f097a3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e3c6ec19-1d84-510b-b44b-43ccb32f6b86","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"60803b59-24a4-5036-b82f-40d837e8e318","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"28cc6229-02b0-596c-b492-3dd868d5230b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7f63de84-1b36-5a2e-b3b3-626df702ff90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69d4244b-043f-55e0-80ac-64b46fe11694","fullItemName":"References","slug":"references","subChapters":[]}]},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}